Axalbion SA
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://axalbion.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)A Study of Efficacy and Safety of AX-8 in Chronic Cough
Phase 2
Completed
- Conditions
- Chronic Cough
- Interventions
- Drug: AX-8, Part 1 of the studyDrug: AX-8, Part 2 of the studyDrug: Placebo, Part 1 of the studyDrug: Placebo, Part 2 of the study
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Axalbion SA
- Target Recruit Count
- 108
- Registration Number
- NCT04866563
- Locations
- 🇬🇧
Axalbion Study Site 4406, Birmingham, England, United Kingdom
🇬🇧Axalbion Study Site 4404, Broughton, England, United Kingdom
🇬🇧Axalbion Study Site 4409, Chelmsford, England, United Kingdom
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AX-8 Part 1Drug: AX-8 Part 2
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Axalbion SA
- Target Recruit Count
- 20
- Registration Number
- NCT04107441
- Locations
- 🇬🇧
Medicines Evaluation Unit (MEU) Ltd, Manchester, United Kingdom
News
No news found